Trials / Completed
CompletedNCT00157911
A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia (0653-042)
A Double-Blind, Randomized, Multicenter, Active-Comparative, 12-Week Study to Assess the Efficacy and Safety of the Drug in Conjunction With Another Drug in Korean Patients With Primary Hypercholesterolemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients undergo 4-week placebo lead-in and diet period, and 12-week treatment period. Clinical efficacy and safety is evaluated at weeks 4, 8 and 12. This study takes approximately 18 weeks for an individual patient to complete including post-visit at week 14.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0653; ezetimibe / Duration of Treatment: 12 weeks | |
| DRUG | Comparator: simvastatin / Duration of Treatment: 12 weeks |
Timeline
- Start date
- 2002-12-01
- Primary completion
- 2003-10-01
- Completion
- 2003-12-01
- First posted
- 2005-09-12
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00157911. Inclusion in this directory is not an endorsement.